Skip to content

Prospective Registry Study on Prognostic Biomarkers and the Impact of Treatment Strategies on Outcomes in Motor Neuron Disease

Prospective Registry Study on Prognostic Biomarkers and the Impact of Treatment Strategies on Outcomes in Motor Neuron Disease

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600117549
Enrollment
Unknown
Registered
2026-01-26
Start date
2026-02-01
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

motor neuron disease

Interventions

Motor Neuron Disease Group:NA

Sponsors

NanJing First Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age >= 18 years; 2. Meet the diagnostic criteria for amyotrophic lateral sclerosis (ALS) as defined by the revised El Escorial criteria (2000), including definite, probable, or probable laboratory-supported ALS, or possible ALS with electrophysiological evidence; 3.Provide signed informed consent.

Exclusion criteria

Exclusion criteria: 1.Patients with incomplete clinical data; 2.Patients with other severe medical conditions, such as recent trauma, severe systemic inflammation, significant hepatic or renal dysfunction, or progressive malignant tumors; 3.Failure to provide signed informed consent.

Design outcomes

Primary

MeasureTime frame
Neurological function impairment score;

Countries

China

Contacts

Public ContactShi Jianquan

NanJing First Hospital

15380998657@163.com+86 25 87726218

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 7, 2026